Kestra Medical shares rise 10.43% intraday after Q2 2026 revenue guidance of $22.2M–$22.6M (+52% YoY) and 50.0% gross margin, and $138M funding raise via 6M share offering for sales, marketing, and R&D.

Kestra Medical surged 10.43% intraday, driven by the company's Q2 fiscal 2026 preliminary revenue guidance of $22.2–$22.6 million (52% YoY growth) with a 50.0% gross margin, and a $138 million follow-on offering of 6 million shares on December 2, 2025, to fund sales, marketing, and R&D.